Unfortunately, a few patients died. They seem to have about a year of cash left, but cash burn is going up from trials unless they can cut costs elsewhere. Also, there has been a 'shakeup' with management, which could mean a period of turmoil, hopefully is doesn't happen or if it does then it's for the better.
Two positives are the disclosure that GSK got another unnamed target nominated for TCR #3 (after NY-ESO & PRAME) and they can now nominate a fourth target with the option of a fifth. For each ADAP gets specified development milestones of $325 million if all MHC classes are exploited. In addition, internal programs are ongoing that relate to the neoantigen field.
News 
Market Data 
Discover 
AI
